PYC Stock Overview
PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia.
PYC Therapeutics Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.061|
|52 Week High||AU$0.16|
|52 Week Low||AU$0.058|
|1 Month Change||-15.28%|
|3 Month Change||-25.61%|
|1 Year Change||-60.65%|
|3 Year Change||69.44%|
|5 Year Change||35.56%|
|Change since IPO||-76.54%|
Recent News & Updates
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
|PYC||AU Biotechs||AU Market|
Return vs Industry: PYC underperformed the Australian Biotechs industry which returned -1.3% over the past year.
Return vs Market: PYC underperformed the Australian Market which returned -8% over the past year.
|PYC Average Weekly Movement||11.7%|
|Biotechs Industry Average Movement||11.7%|
|Market Average Movement||10.5%|
|10% most volatile stocks in AU Market||17.6%|
|10% least volatile stocks in AU Market||4.6%|
Stable Share Price: PYC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: PYC's weekly volatility (12%) has been stable over the past year.
About the Company
PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company’s preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for retinal and central nervous system diseases.
PYC Therapeutics Limited Fundamentals Summary
|PYC fundamental statistics|
Is PYC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PYC income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0053|
|Net Profit Margin||-185.43%|
How did PYC perform over the long term?See historical performance and comparison